Kevin N. Heller

1.7k total citations · 1 hit paper
19 papers, 1.3k citations indexed

About

Kevin N. Heller is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Kevin N. Heller has authored 19 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Immunology. Recurrent topics in Kevin N. Heller's work include Cancer Immunotherapy and Biomarkers (7 papers), Viral-associated cancers and disorders (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Kevin N. Heller is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Viral-associated cancers and disorders (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Kevin N. Heller collaborates with scholars based in United States, Germany and Italy. Kevin N. Heller's co-authors include Omid Hamid, Jedd D. Wolchok, Mario Sznol, David F. McDermott, F. Stephen Hodi, Donald P. Lawrence, Kim Margolin, Igor Puzanov, Jon Richards and Ágnes Balogh and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kevin N. Heller

19 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

2012 826 citations Kim Margolin, Marc S. Ernstoff et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Kevin N. Heller

Since Specialization

Citations

This map shows the geographic impact of Kevin N. Heller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin N. Heller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin N. Heller more than expected).

Fields of papers citing papers by Kevin N. Heller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin N. Heller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin N. Heller. The network helps show where Kevin N. Heller may publish in the future.

Co-authorship network of co-authors of Kevin N. Heller

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin N. Heller. A scholar is included among the top collaborators of Kevin N. Heller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin N. Heller. Kevin N. Heller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	743 INCLINE-101: preliminary safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TAC-001 (TLR9 agonist conjugated to a CD22 mAb) in patients with advanced or metastatic solid tumors 2023 ·SHILAP Revista de lepidopterología ·Cesar A. Perez, Jason T. Henry, Sunnie S. Y. Kim, Anthony B. El-Khoueiry, Martin Gutierrez, Anna C. Pavlick, Joshua Lee, Sangeetha Bollini, Feng Jin, Ons Harrabi, Kevin N. Heller, (unknown)	1
2	Preliminary Data from a Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning Is Well-Tolerated, Facilitates Chimerism and Clearance of Minimal Residual Disease in Older Adults with MDS/AML Undergoing Allogeneic HCT 2022 ·Transplantation and Cellular Therapy ·Lori Muffly, Catherine J. Lee, (unknown), Ankur Varma, Bart L. Scott, Hye‐Sook Kwon, (unknown), (unknown), Mamatha M. Reddy, Kevin N. Heller, Judith A. Shizuru, Wendy W. Pang, Andrew Artz	2
3	Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors. 2020 ·Journal of Clinical Oncology ·Martin Gutierrez, Omid Hamid, Elaine Shum, David R. Wise, Arjun Vasant Balar, Jeffrey S. Weber, Patricia LoRusso, Saba Shafi, David L. Rimm, Anthony W. Tolcher, (unknown), Melanie Dujka, Kevin N. Heller	9
4	Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer 2016 ·European Thyroid Journal ·Lars Bastholt, Michael C. Kreißl, Dagmar Führer, Ana Luiza Maia, Laura D. Locati, Léa Maria Zanini Maciel, (unknown), Kevin N. Heller, Alan Webster, Rossella Elisei	13
5	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial breakdown → 2012 ·The Lancet Oncology ·Kim Margolin, Marc S. Ernstoff, Omid Hamid, Donald P. Lawrence, David F. McDermott, Igor Puzanov, Jedd D. Wolchok, Joseph I. Clark, Mario Sznol, Theodore F. Logan, Jon Richards, (unknown), Ágnes Balogh, Kevin N. Heller, F. Stephen Hodi	826
6	Food Increased the Bioavailability of BMS‐690514, an Orally Active EGFR/HER2/VEGF Receptor Kinase Inhibitor, in Healthy Subjects 2011 ·The Journal of Clinical Pharmacology ·Blisse Vakkalagadda, (unknown), Christoph M. Ahlers, (unknown), (unknown), Vikram Roongta, Kevin N. Heller, George Derbin, Steven Zhang	4
7	Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. 2011 ·Journal of Clinical Oncology ·Kevin N. Heller, Anne C. Pavlick, F. Stephen Hodi, John A. Thompson, Kim Margolin, Donald P. Lawrence, David F. McDermott, Wolfram E. Samlowski, (unknown), Maria Karasarides	29
8	Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma 2011 ·Journal of Clinical Oncology ·Matthew M. Burke, Harriet M. Kluger, Marjorie Golden, Kevin N. Heller, Axel Hoos, Mario Sznol	31
9	Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. 2011 ·Journal of Clinical Oncology ·Steven O’Day, Jeffrey S. Weber, J. D. Wolchok, Jon Richards, Paul Lorigan, David F. McDermott, Walter J. Urba, (unknown), Kevin N. Heller, (unknown), Axel Hauschild	25
10	9306 ORAL Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases 2011 ·European Journal of Cancer ·Kim Margolin, F. Stephen Hodi, David F. McDermott, David Lawrence, Omid Hamid, Igor Puzanov, John A. Thompson, Marc S. Ernstoff, (unknown), Kevin N. Heller	1
11	Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans 2010 ·Drug Metabolism and Disposition ·Lisa J. Christopher, Haizheng Hong, Blisse Vakkalagadda, Pamela L. Clemens, Hong Su, Vikram Roongta, Alban J. Allentoff, (unknown), Kevin N. Heller, Christopher Harbison, Ramaswamy A. Iyer, W. Griffith Humphreys, Tai‐Tong Wong, Steven Zhang	16
12	Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. 2010 ·Journal of Clinical Oncology ·Donald P. Lawrence, Omid Hamid, David F. McDermott, Igor Puzanov, Mario Sznol, Jordan J. Clark, (unknown), F. Stephen Hodi, Kevin N. Heller, Kim Margolin	24
13	Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. 2010 ·PubMed ·Jedd D. Wolchok, Jeffrey S. Weber, Omid Hamid, Célèste Lebbé, Michele Maio, Dirk Schadendorf, Veerle de Pril, Kevin N. Heller, Tai‐Tsang Chen, Ramy Ibrahim, Axel Hoos, Steven O’Day	95
14	Children with endemic Burkitt lymphoma are deficient in EBNA1‐specific IFN‐γ T cell responses 2008 ·International Journal of Cancer ·Ann M. Moormann, Kevin N. Heller, Kiprotich Chelimo, Paula Embury, Robert Ploutz‐Snyder, Juliana A. Otieno, Margaret Oduor, Christian Münz, Rosemary Rochford	49
15	Patients with Epstein Barr virus‐positive lymphomas have decreased CD4⁺ T‐cell responses to the viral nuclear antigen 1 2008 ·International Journal of Cancer ·Kevin N. Heller, Frida Arrey, Peter G. Steinherz, Carol S. Portlock, Amy Chadburn, Kara M. Kelly, Christian Münz	27
16	EBV-positive lymphoma patients have a selective deficiency in EBV immunity 2007 ·Journal of Clinical Oncology ·Kevin N. Heller, Peter G. Steinherz, C. Portlock, Christian Münz	1
17	Virus-specific CD4+ T cells: ready for direct attack 2006 ·The Journal of Experimental Medicine ·Kevin N. Heller, Cagan Gurer, Christian Münz	73
18	Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers 2006 ·Blood ·Kevin N. Heller, Jenica Upshaw, (unknown), Henry Zebroski, Christian Münz	41
19	Primary Follicular Lymphoma of the Testis 2004 ·Journal of Pediatric Hematology/Oncology ·Kevin N. Heller, Julie Teruya‐Feldstein, Michael P. LaQuaglia, Leonard H. Wexler	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact